4.04
0.01 (0.25%)
| Previous Close | 4.03 |
| Open | 4.03 |
| Volume | 520,285 |
| Avg. Volume (3M) | 2,408,868 |
| Market Cap | 223,255,648 |
| Price / Earnings (Forward) | 8.95 |
| Price / Sales | 3.00 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -79,817.02% |
| Diluted EPS (TTM) | -1.83 |
| Quarterly Revenue Growth (YOY) | 32.30% |
| Current Ratio (MRQ) | 0.290 |
| Operating Cash Flow (TTM) | -30.76 M |
| Levered Free Cash Flow (TTM) | -22.81 M |
| Return on Assets (TTM) | -633.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Checkpoint Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.50 |
|
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.83% |
| % Held by Institutions | 33.01% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wealth Enhancement Advisory Services, Llc | 31 Dec 2024 | 425,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 4.80 (D. Boral Capital, 18.81%) | Buy |
| Median | 4.10 (1.49%) | |
| Low | 4.10 (Lake Street, 1.49%) | Hold |
| 4.10 (HC Wainwright & Co., 1.49%) | Hold | |
| Average | 4.33 (7.18%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 4.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 31 Mar 2025 | 4.80 (18.81%) | Buy | 4.04 |
| 10 Mar 2025 | 4.80 (18.81%) | Buy | 3.98 | |
| HC Wainwright & Co. | 11 Mar 2025 | 4.10 (1.49%) | Hold | 4.00 |
| Lake Street | 10 Mar 2025 | 4.10 (1.49%) | Hold | 3.98 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Mar 2025 | Announcement | Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates |
| 09 Mar 2025 | Announcement | Sun Pharma to Acquire Checkpoint Therapeutics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |